Rodman & Renshaw Terminates Coverage of China Pharma Holdings

by Emily Austin, Benzinga Staff Writer

July 26, 2011 3:39 AM | 13 seconds read | Make a Comment

Rodman & Renshaw terminated its coverage of China Pharma Holdings

CPHI

. The rating agency's last rating placed on the company's stock was Market Outperform with a price target of $6. On Monday, CPHI closed the day at $2.14.

Market News and Data brought to you by Benzinga APIs

Posted In: Analyst Ratings Rodman and Renshaw

Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Rodman & Renshaw Terminates Coverage of China Pharma Holdings